nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—ABCG2—Dexamethasone—psoriatic arthritis	0.0716	0.0972	CbGbCtD
Regorafenib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0683	0.0926	CbGbCtD
Regorafenib—ABCG2—Methotrexate—psoriatic arthritis	0.0576	0.0781	CbGbCtD
Regorafenib—CYP2C19—Prednisone—psoriatic arthritis	0.0513	0.0696	CbGbCtD
Regorafenib—CYP2B6—Dexamethasone—psoriatic arthritis	0.0504	0.0683	CbGbCtD
Regorafenib—ABCB1—Betamethasone—psoriatic arthritis	0.0444	0.0602	CbGbCtD
Regorafenib—ABCB1—Prednisolone—psoriatic arthritis	0.0438	0.0594	CbGbCtD
Regorafenib—ABCB1—Prednisone—psoriatic arthritis	0.0414	0.0561	CbGbCtD
Regorafenib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0409	0.0555	CbGbCtD
Regorafenib—CYP2C8—Dexamethasone—psoriatic arthritis	0.0382	0.0518	CbGbCtD
Regorafenib—CYP2C19—Dexamethasone—psoriatic arthritis	0.032	0.0434	CbGbCtD
Regorafenib—CYP3A4—Triamcinolone—psoriatic arthritis	0.031	0.0421	CbGbCtD
Regorafenib—CYP2C9—Dexamethasone—psoriatic arthritis	0.0266	0.0361	CbGbCtD
Regorafenib—CYP3A4—Betamethasone—psoriatic arthritis	0.0266	0.0361	CbGbCtD
Regorafenib—CYP3A4—Prednisolone—psoriatic arthritis	0.0263	0.0356	CbGbCtD
Regorafenib—ABCB1—Dexamethasone—psoriatic arthritis	0.0258	0.035	CbGbCtD
Regorafenib—CYP3A4—Prednisone—psoriatic arthritis	0.0248	0.0336	CbGbCtD
Regorafenib—ABCB1—Methotrexate—psoriatic arthritis	0.0208	0.0282	CbGbCtD
Regorafenib—CYP3A4—Dexamethasone—psoriatic arthritis	0.0155	0.021	CbGbCtD
Regorafenib—Proteinuria—Auranofin—psoriatic arthritis	0.00608	0.0382	CcSEcCtD
Regorafenib—Protein urine present—Auranofin—psoriatic arthritis	0.006	0.0376	CcSEcCtD
Regorafenib—Infarction—Methylprednisolone—psoriatic arthritis	0.00563	0.0354	CcSEcCtD
Regorafenib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—CARD14—psoriatic arthritis	0.00504	0.0531	CbGpPWpGaD
Regorafenib—MAPK11—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.00344	0.0362	CbGpPWpGaD
Regorafenib—Neutropenia—Auranofin—psoriatic arthritis	0.00314	0.0197	CcSEcCtD
Regorafenib—MAPK11—activated TAK1 mediates p38 MAPK activation—NOD2—psoriatic arthritis	0.00307	0.0323	CbGpPWpGaD
Regorafenib—Weight decreased—Auranofin—psoriatic arthritis	0.00303	0.019	CcSEcCtD
Regorafenib—MAPK11—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.00301	0.0318	CbGpPWpGaD
Regorafenib—Stomatitis—Auranofin—psoriatic arthritis	0.00291	0.0183	CcSEcCtD
Regorafenib—PDGFRA—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.00257	0.0271	CbGpPWpGaD
Regorafenib—Lymphopenia—Prednisone—psoriatic arthritis	0.00242	0.0152	CcSEcCtD
Regorafenib—Alopecia—Auranofin—psoriatic arthritis	0.00237	0.0149	CcSEcCtD
Regorafenib—Anaemia—Auranofin—psoriatic arthritis	0.00216	0.0136	CcSEcCtD
Regorafenib—Leukopenia—Auranofin—psoriatic arthritis	0.00209	0.0131	CcSEcCtD
Regorafenib—Hypothyroidism—Prednisone—psoriatic arthritis	0.00193	0.0121	CcSEcCtD
Regorafenib—MAPK11—NOD1/2 Signaling Pathway—NOD2—psoriatic arthritis	0.0019	0.02	CbGpPWpGaD
Regorafenib—Mucosal inflammation—Methotrexate—psoriatic arthritis	0.00187	0.0117	CcSEcCtD
Regorafenib—Thrombocytopenia—Auranofin—psoriatic arthritis	0.00187	0.0117	CcSEcCtD
Regorafenib—Polyp—Methotrexate—psoriatic arthritis	0.0017	0.0107	CcSEcCtD
Regorafenib—Decreased appetite—Auranofin—psoriatic arthritis	0.00166	0.0104	CcSEcCtD
Regorafenib—Nail disorder—Methotrexate—psoriatic arthritis	0.0016	0.01	CcSEcCtD
Regorafenib—Gastrointestinal pain—Auranofin—psoriatic arthritis	0.00156	0.00979	CcSEcCtD
Regorafenib—Cyst—Methotrexate—psoriatic arthritis	0.00155	0.00972	CcSEcCtD
Regorafenib—RET—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	0.00153	0.0162	CbGpPWpGaD
Regorafenib—Abdominal pain—Auranofin—psoriatic arthritis	0.00151	0.00946	CcSEcCtD
Regorafenib—Endocrine disorder—Prednisone—psoriatic arthritis	0.00149	0.00938	CcSEcCtD
Regorafenib—Hepatotoxicity—Methotrexate—psoriatic arthritis	0.00134	0.00841	CcSEcCtD
Regorafenib—Diarrhoea—Auranofin—psoriatic arthritis	0.0013	0.00819	CcSEcCtD
Regorafenib—MAPK11—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.00129	0.0136	CbGpPWpGaD
Regorafenib—TEK—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.00129	0.0136	CbGpPWpGaD
Regorafenib—Vomiting—Auranofin—psoriatic arthritis	0.00121	0.00761	CcSEcCtD
Regorafenib—Rash—Auranofin—psoriatic arthritis	0.0012	0.00755	CcSEcCtD
Regorafenib—Dermatitis—Auranofin—psoriatic arthritis	0.0012	0.00754	CcSEcCtD
Regorafenib—MAPK11—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.00118	0.0125	CbGpPWpGaD
Regorafenib—Proteinuria—Methotrexate—psoriatic arthritis	0.00118	0.00739	CcSEcCtD
Regorafenib—MAPK11—Glucocorticoid receptor regulatory network—IL13—psoriatic arthritis	0.00118	0.0124	CbGpPWpGaD
Regorafenib—Protein urine present—Methotrexate—psoriatic arthritis	0.00116	0.00729	CcSEcCtD
Regorafenib—Musculoskeletal stiffness—Methotrexate—psoriatic arthritis	0.00115	0.00724	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Methotrexate—psoriatic arthritis	0.00114	0.00714	CcSEcCtD
Regorafenib—Dry skin—Prednisolone—psoriatic arthritis	0.00113	0.00712	CcSEcCtD
Regorafenib—Nausea—Auranofin—psoriatic arthritis	0.00113	0.00711	CcSEcCtD
Regorafenib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.00113	0.0119	CbGpPWpGaD
Regorafenib—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.00113	0.0119	CbGpPWpGaD
Regorafenib—MAPK11—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.00112	0.0118	CbGpPWpGaD
Regorafenib—Hyperuricaemia—Methotrexate—psoriatic arthritis	0.00112	0.007	CcSEcCtD
Regorafenib—BRAF—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.00112	0.0118	CbGpPWpGaD
Regorafenib—Blood uric acid increased—Methotrexate—psoriatic arthritis	0.00105	0.00661	CcSEcCtD
Regorafenib—PDGFRA—Allograft Rejection—HLA-C—psoriatic arthritis	0.00104	0.011	CbGpPWpGaD
Regorafenib—PDGFRA—Allograft Rejection—IL13—psoriatic arthritis	0.00104	0.0109	CbGpPWpGaD
Regorafenib—DDR2—skin of body—psoriatic arthritis	0.00102	0.118	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.001	0.00628	CcSEcCtD
Regorafenib—RET—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.00097	0.0102	CbGpPWpGaD
Regorafenib—MAPK11—IL6-mediated signaling events—CRP—psoriatic arthritis	0.000967	0.0102	CbGpPWpGaD
Regorafenib—PDGFRA—Allograft Rejection—IL17A—psoriatic arthritis	0.000953	0.01	CbGpPWpGaD
Regorafenib—RAF1—Leptin signaling pathway—REL—psoriatic arthritis	0.000948	0.00999	CbGpPWpGaD
Regorafenib—Dry skin—Betamethasone—psoriatic arthritis	0.000946	0.00594	CcSEcCtD
Regorafenib—Dry skin—Dexamethasone—psoriatic arthritis	0.000946	0.00594	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisolone—psoriatic arthritis	0.00094	0.0059	CcSEcCtD
Regorafenib—Hypokalaemia—Dexamethasone—psoriatic arthritis	0.000939	0.0059	CcSEcCtD
Regorafenib—Hypokalaemia—Betamethasone—psoriatic arthritis	0.000939	0.0059	CcSEcCtD
Regorafenib—MAPK11—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000936	0.00987	CbGpPWpGaD
Regorafenib—Neoplasm—Methotrexate—psoriatic arthritis	0.000936	0.00587	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisolone—psoriatic arthritis	0.000935	0.00586	CcSEcCtD
Regorafenib—PDGFRA—Allograft Rejection—IL12B—psoriatic arthritis	0.000886	0.00934	CbGpPWpGaD
Regorafenib—Infestation—Methylprednisolone—psoriatic arthritis	0.000875	0.00549	CcSEcCtD
Regorafenib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.000875	0.00549	CcSEcCtD
Regorafenib—Acute coronary syndrome—Triamcinolone—psoriatic arthritis	0.000864	0.00542	CcSEcCtD
Regorafenib—Acute coronary syndrome—Methylprednisolone—psoriatic arthritis	0.000862	0.00541	CcSEcCtD
Regorafenib—Haemoglobin—Prednisolone—psoriatic arthritis	0.00086	0.0054	CcSEcCtD
Regorafenib—Myocardial infarction—Triamcinolone—psoriatic arthritis	0.000859	0.00539	CcSEcCtD
Regorafenib—Myocardial infarction—Methylprednisolone—psoriatic arthritis	0.000858	0.00538	CcSEcCtD
Regorafenib—Haemorrhage—Prednisolone—psoriatic arthritis	0.000856	0.00537	CcSEcCtD
Regorafenib—MAPK11—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000847	0.00893	CbGpPWpGaD
Regorafenib—MAPK11—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000846	0.00892	CbGpPWpGaD
Regorafenib—MAPK11—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000839	0.00884	CbGpPWpGaD
Regorafenib—Dry skin—Prednisone—psoriatic arthritis	0.000824	0.00517	CcSEcCtD
Regorafenib—MAPK11—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000824	0.00868	CbGpPWpGaD
Regorafenib—RAF1—TCR Signaling Pathway—REL—psoriatic arthritis	0.000819	0.00864	CbGpPWpGaD
Regorafenib—Hypokalaemia—Prednisone—psoriatic arthritis	0.000818	0.00513	CcSEcCtD
Regorafenib—TEK—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	0.000809	0.00852	CbGpPWpGaD
Regorafenib—Weight decreased—Betamethasone—psoriatic arthritis	0.000807	0.00507	CcSEcCtD
Regorafenib—Weight decreased—Dexamethasone—psoriatic arthritis	0.000807	0.00507	CcSEcCtD
Regorafenib—RAF1—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.000805	0.00848	CbGpPWpGaD
Regorafenib—MAPK11—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000795	0.00838	CbGpPWpGaD
Regorafenib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.000793	0.00498	CcSEcCtD
Regorafenib—Haemoglobin—Triamcinolone—psoriatic arthritis	0.000791	0.00496	CcSEcCtD
Regorafenib—Haemoglobin—Methylprednisolone—psoriatic arthritis	0.000789	0.00495	CcSEcCtD
Regorafenib—Haemorrhage—Triamcinolone—psoriatic arthritis	0.000787	0.00494	CcSEcCtD
Regorafenib—Haemorrhage—Methylprednisolone—psoriatic arthritis	0.000785	0.00493	CcSEcCtD
Regorafenib—Acute coronary syndrome—Betamethasone—psoriatic arthritis	0.000784	0.00492	CcSEcCtD
Regorafenib—Acute coronary syndrome—Dexamethasone—psoriatic arthritis	0.000784	0.00492	CcSEcCtD
Regorafenib—MAPK11—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000781	0.00824	CbGpPWpGaD
Regorafenib—Myocardial infarction—Dexamethasone—psoriatic arthritis	0.00078	0.00489	CcSEcCtD
Regorafenib—Myocardial infarction—Betamethasone—psoriatic arthritis	0.00078	0.00489	CcSEcCtD
Regorafenib—DDR2—tendon—psoriatic arthritis	0.000773	0.0899	CbGeAlD
Regorafenib—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.000772	0.00484	CcSEcCtD
Regorafenib—RAF1—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000772	0.00813	CbGpPWpGaD
Regorafenib—RAF1—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.00076	0.00801	CbGpPWpGaD
Regorafenib—MAPK11—MyD88-independent cascade—NOD2—psoriatic arthritis	0.00075	0.0079	CbGpPWpGaD
Regorafenib—MAPK11—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000735	0.00775	CbGpPWpGaD
Regorafenib—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000729	0.00457	CcSEcCtD
Regorafenib—Neutropenia—Prednisone—psoriatic arthritis	0.000727	0.00456	CcSEcCtD
Regorafenib—Haemoglobin—Betamethasone—psoriatic arthritis	0.000718	0.0045	CcSEcCtD
Regorafenib—Haemoglobin—Dexamethasone—psoriatic arthritis	0.000718	0.0045	CcSEcCtD
Regorafenib—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000714	0.00448	CcSEcCtD
Regorafenib—Haemorrhage—Betamethasone—psoriatic arthritis	0.000714	0.00448	CcSEcCtD
Regorafenib—Angiopathy—Methylprednisolone—psoriatic arthritis	0.000713	0.00447	CcSEcCtD
Regorafenib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000708	0.00444	CcSEcCtD
Regorafenib—Weight decreased—Prednisone—psoriatic arthritis	0.000703	0.00441	CcSEcCtD
Regorafenib—RAF1—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.00069	0.00727	CbGpPWpGaD
Regorafenib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000684	0.00429	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.000683	0.00429	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisone—psoriatic arthritis	0.000679	0.00426	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.000677	0.00425	CcSEcCtD
Regorafenib—MAPK11—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000674	0.00711	CbGpPWpGaD
Regorafenib—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000669	0.00705	CbGpPWpGaD
Regorafenib—MAPK11—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.000664	0.007	CbGpPWpGaD
Regorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000661	0.00696	CbGpPWpGaD
Regorafenib—KIT—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000657	0.00693	CbGpPWpGaD
Regorafenib—Angiopathy—Betamethasone—psoriatic arthritis	0.000648	0.00407	CcSEcCtD
Regorafenib—Angiopathy—Dexamethasone—psoriatic arthritis	0.000648	0.00407	CcSEcCtD
Regorafenib—Hypertension—Prednisolone—psoriatic arthritis	0.000643	0.00404	CcSEcCtD
Regorafenib—MAPK11—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000634	0.00669	CbGpPWpGaD
Regorafenib—Alopecia—Betamethasone—psoriatic arthritis	0.000631	0.00396	CcSEcCtD
Regorafenib—Alopecia—Dexamethasone—psoriatic arthritis	0.000631	0.00396	CcSEcCtD
Regorafenib—PDGFRA—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000627	0.00661	CbGpPWpGaD
Regorafenib—Haemoglobin—Prednisone—psoriatic arthritis	0.000625	0.00392	CcSEcCtD
Regorafenib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000624	0.00658	CbGpPWpGaD
Regorafenib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000622	0.00656	CbGpPWpGaD
Regorafenib—Haemorrhage—Prednisone—psoriatic arthritis	0.000622	0.0039	CcSEcCtD
Regorafenib—PDGFRA—Allograft Rejection—HLA-B—psoriatic arthritis	0.000616	0.0065	CbGpPWpGaD
Regorafenib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000611	0.00384	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—psoriatic arthritis	0.000607	0.00381	CcSEcCtD
Regorafenib—Hypertension—Triamcinolone—psoriatic arthritis	0.000592	0.00371	CcSEcCtD
Regorafenib—FGFR2—B Cell Activation—REL—psoriatic arthritis	0.000591	0.00623	CbGpPWpGaD
Regorafenib—Hypertension—Methylprednisolone—psoriatic arthritis	0.00059	0.0037	CcSEcCtD
Regorafenib—FGFR2—DAP12 interactions—HLA-C—psoriatic arthritis	0.000588	0.0062	CbGpPWpGaD
Regorafenib—KIT—B Cell Activation—REL—psoriatic arthritis	0.000581	0.00612	CbGpPWpGaD
Regorafenib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000579	0.00363	CcSEcCtD
Regorafenib—Infestation—Methotrexate—psoriatic arthritis	0.000579	0.00363	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000578	0.00363	CcSEcCtD
Regorafenib—KIT—DAP12 interactions—HLA-C—psoriatic arthritis	0.000577	0.00609	CbGpPWpGaD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000574	0.0036	CcSEcCtD
Regorafenib—Dry mouth—Triamcinolone—psoriatic arthritis	0.00057	0.00358	CcSEcCtD
Regorafenib—MAPK11—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000565	0.00595	CbGpPWpGaD
Regorafenib—Stomatitis—Methotrexate—psoriatic arthritis	0.000564	0.00354	CcSEcCtD
Regorafenib—Angiopathy—Prednisone—psoriatic arthritis	0.000564	0.00354	CcSEcCtD
Regorafenib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000561	0.00591	CbGpPWpGaD
Regorafenib—Infection—Triamcinolone—psoriatic arthritis	0.000556	0.00349	CcSEcCtD
Regorafenib—Infection—Methylprednisolone—psoriatic arthritis	0.000554	0.00348	CcSEcCtD
Regorafenib—FGFR1—B Cell Activation—REL—psoriatic arthritis	0.000551	0.00581	CbGpPWpGaD
Regorafenib—PDGFRA—B Cell Activation—REL—psoriatic arthritis	0.00055	0.00579	CbGpPWpGaD
Regorafenib—Alopecia—Prednisone—psoriatic arthritis	0.00055	0.00345	CcSEcCtD
Regorafenib—FGFR1—DAP12 interactions—HLA-C—psoriatic arthritis	0.000548	0.00578	CbGpPWpGaD
Regorafenib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000548	0.00344	CcSEcCtD
Regorafenib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000547	0.00343	CcSEcCtD
Regorafenib—PDGFRA—DAP12 interactions—HLA-C—psoriatic arthritis	0.000547	0.00576	CbGpPWpGaD
Regorafenib—BRAF—tendon—psoriatic arthritis	0.000546	0.0635	CbGeAlD
Regorafenib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000542	0.0034	CcSEcCtD
Regorafenib—Malnutrition—Prednisone—psoriatic arthritis	0.000541	0.0034	CcSEcCtD
Regorafenib—Hypertension—Betamethasone—psoriatic arthritis	0.000537	0.00337	CcSEcCtD
Regorafenib—Hypertension—Dexamethasone—psoriatic arthritis	0.000537	0.00337	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000522	0.00328	CcSEcCtD
Regorafenib—EPHX2—tendon—psoriatic arthritis	0.000522	0.0607	CbGeAlD
Regorafenib—PDGFRA—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000522	0.0055	CbGpPWpGaD
Regorafenib—Pain—Prednisolone—psoriatic arthritis	0.00052	0.00326	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—psoriatic arthritis	0.00052	0.00326	CcSEcCtD
Regorafenib—FGFR2—skin of body—psoriatic arthritis	0.000519	0.0603	CbGeAlD
Regorafenib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000513	0.00322	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—psoriatic arthritis	0.00051	0.0032	CcSEcCtD
Regorafenib—Infection—Dexamethasone—psoriatic arthritis	0.000504	0.00316	CcSEcCtD
Regorafenib—Infection—Betamethasone—psoriatic arthritis	0.000504	0.00316	CcSEcCtD
Regorafenib—Anaemia—Prednisone—psoriatic arthritis	0.0005	0.00314	CcSEcCtD
Regorafenib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000498	0.00312	CcSEcCtD
Regorafenib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000498	0.00312	CcSEcCtD
Regorafenib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000497	0.00312	CcSEcCtD
Regorafenib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000497	0.00312	CcSEcCtD
Regorafenib—PDGFRB—B Cell Activation—REL—psoriatic arthritis	0.000495	0.00522	CbGpPWpGaD
Regorafenib—PDGFRB—DAP12 interactions—HLA-C—psoriatic arthritis	0.000492	0.00519	CbGpPWpGaD
Regorafenib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000491	0.00308	CcSEcCtD
Regorafenib—MAPK11—Innate Immune System—MEFV—psoriatic arthritis	0.000486	0.00512	CbGpPWpGaD
Regorafenib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000482	0.00303	CcSEcCtD
Regorafenib—Fatigue—Triamcinolone—psoriatic arthritis	0.000482	0.00303	CcSEcCtD
Regorafenib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000481	0.00302	CcSEcCtD
Regorafenib—RAF1—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000479	0.00505	CbGpPWpGaD
Regorafenib—Pain—Triamcinolone—psoriatic arthritis	0.000478	0.003	CcSEcCtD
Regorafenib—RAF1—skin of body—psoriatic arthritis	0.000478	0.0556	CbGeAlD
Regorafenib—Angiopathy—Methotrexate—psoriatic arthritis	0.000472	0.00296	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000468	0.00294	CcSEcCtD
Regorafenib—Hypertension—Prednisone—psoriatic arthritis	0.000467	0.00293	CcSEcCtD
Regorafenib—FGFR1—tendon—psoriatic arthritis	0.000464	0.054	CbGeAlD
Regorafenib—RAF1—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000461	0.00485	CbGpPWpGaD
Regorafenib—Alopecia—Methotrexate—psoriatic arthritis	0.000459	0.00288	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000458	0.00287	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000456	0.00286	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—psoriatic arthritis	0.000452	0.00284	CcSEcCtD
Regorafenib—FGFR2—Innate Immune System—MEFV—psoriatic arthritis	0.000446	0.0047	CbGpPWpGaD
Regorafenib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000442	0.00277	CcSEcCtD
Regorafenib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000441	0.00277	CcSEcCtD
Regorafenib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000441	0.00277	CcSEcCtD
Regorafenib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000441	0.00277	CcSEcCtD
Regorafenib—Infection—Prednisone—psoriatic arthritis	0.000439	0.00275	CcSEcCtD
Regorafenib—RAF1—DAP12 interactions—HLA-C—psoriatic arthritis	0.000439	0.00463	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—MEFV—psoriatic arthritis	0.000438	0.00462	CbGpPWpGaD
Regorafenib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000438	0.00275	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000438	0.00275	CcSEcCtD
Regorafenib—Fatigue—Dexamethasone—psoriatic arthritis	0.000437	0.00275	CcSEcCtD
Regorafenib—Fatigue—Betamethasone—psoriatic arthritis	0.000437	0.00275	CcSEcCtD
Regorafenib—Pain—Dexamethasone—psoriatic arthritis	0.000434	0.00272	CcSEcCtD
Regorafenib—Pain—Betamethasone—psoriatic arthritis	0.000434	0.00272	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000433	0.00272	CcSEcCtD
Regorafenib—Skin disorder—Prednisone—psoriatic arthritis	0.000429	0.00269	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—psoriatic arthritis	0.000418	0.00262	CcSEcCtD
Regorafenib—FGFR1—Innate Immune System—MEFV—psoriatic arthritis	0.000416	0.00438	CbGpPWpGaD
Regorafenib—RET—tendon—psoriatic arthritis	0.000416	0.0483	CbGeAlD
Regorafenib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000415	0.0026	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000415	0.0026	CcSEcCtD
Regorafenib—PDGFRA—Innate Immune System—MEFV—psoriatic arthritis	0.000415	0.00437	CbGpPWpGaD
Regorafenib—Leukopenia—Methotrexate—psoriatic arthritis	0.000405	0.00254	CcSEcCtD
Regorafenib—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000402	0.00423	CbGpPWpGaD
Regorafenib—Asthenia—Triamcinolone—psoriatic arthritis	0.000401	0.00252	CcSEcCtD
Regorafenib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000401	0.00252	CcSEcCtD
Regorafenib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000401	0.00252	CcSEcCtD
Regorafenib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000401	0.00252	CcSEcCtD
Regorafenib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000401	0.00252	CcSEcCtD
Regorafenib—Asthenia—Methylprednisolone—psoriatic arthritis	0.0004	0.00251	CcSEcCtD
Regorafenib—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	0.000395	0.00416	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	0.000392	0.00413	CbGpPWpGaD
Regorafenib—EPHA2—tendon—psoriatic arthritis	0.000388	0.0451	CbGeAlD
Regorafenib—Decreased appetite—Prednisone—psoriatic arthritis	0.000384	0.00241	CcSEcCtD
Regorafenib—Rash—Prednisolone—psoriatic arthritis	0.000383	0.00241	CcSEcCtD
Regorafenib—Dermatitis—Prednisolone—psoriatic arthritis	0.000383	0.0024	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000383	0.0024	CcSEcCtD
Regorafenib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000382	0.0024	CcSEcCtD
Regorafenib—Fatigue—Prednisone—psoriatic arthritis	0.000381	0.00239	CcSEcCtD
Regorafenib—Headache—Prednisolone—psoriatic arthritis	0.000381	0.00239	CcSEcCtD
Regorafenib—TEK—tendon—psoriatic arthritis	0.000379	0.044	CbGeAlD
Regorafenib—PDGFRB—Innate Immune System—MEFV—psoriatic arthritis	0.000374	0.00394	CbGpPWpGaD
Regorafenib—Infection—Methotrexate—psoriatic arthritis	0.000367	0.0023	CcSEcCtD
Regorafenib—FLT1—tendon—psoriatic arthritis	0.000366	0.0426	CbGeAlD
Regorafenib—RET—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	0.000365	0.00385	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—MEFV—psoriatic arthritis	0.000364	0.00384	CbGpPWpGaD
Regorafenib—Asthenia—Betamethasone—psoriatic arthritis	0.000364	0.00228	CcSEcCtD
Regorafenib—Asthenia—Dexamethasone—psoriatic arthritis	0.000364	0.00228	CcSEcCtD
Regorafenib—RAF1—tendon—psoriatic arthritis	0.000364	0.0423	CbGeAlD
Regorafenib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000362	0.00227	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000362	0.00227	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000361	0.00227	CcSEcCtD
Regorafenib—Nausea—Prednisolone—psoriatic arthritis	0.000361	0.00227	CcSEcCtD
Regorafenib—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	0.000361	0.0038	CbGpPWpGaD
Regorafenib—KIT—skin of body—psoriatic arthritis	0.00036	0.0419	CbGeAlD
Regorafenib—Skin disorder—Methotrexate—psoriatic arthritis	0.000359	0.00225	CcSEcCtD
Regorafenib—Vomiting—Triamcinolone—psoriatic arthritis	0.000356	0.00223	CcSEcCtD
Regorafenib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000355	0.00223	CcSEcCtD
Regorafenib—FGFR2—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000354	0.00374	CbGpPWpGaD
Regorafenib—Rash—Triamcinolone—psoriatic arthritis	0.000353	0.00221	CcSEcCtD
Regorafenib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000352	0.00221	CcSEcCtD
Regorafenib—Rash—Methylprednisolone—psoriatic arthritis	0.000352	0.00221	CcSEcCtD
Regorafenib—PDGFRB—skin of body—psoriatic arthritis	0.000352	0.0409	CbGeAlD
Regorafenib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000351	0.00221	CcSEcCtD
Regorafenib—Headache—Triamcinolone—psoriatic arthritis	0.00035	0.0022	CcSEcCtD
Regorafenib—Headache—Methylprednisolone—psoriatic arthritis	0.00035	0.00219	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—psoriatic arthritis	0.000349	0.00219	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—psoriatic arthritis	0.000349	0.00219	CcSEcCtD
Regorafenib—FGFR2—DAP12 interactions—HLA-B—psoriatic arthritis	0.000348	0.00366	CbGpPWpGaD
Regorafenib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000347	0.00218	CcSEcCtD
Regorafenib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000347	0.00218	CcSEcCtD
Regorafenib—PDGFRA—tendon—psoriatic arthritis	0.000343	0.0399	CbGeAlD
Regorafenib—KIT—DAP12 interactions—HLA-B—psoriatic arthritis	0.000341	0.0036	CbGpPWpGaD
Regorafenib—NTRK1—Circadian rythm related genes—NOS2—psoriatic arthritis	0.000339	0.00358	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	0.000336	0.00354	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—MEFV—psoriatic arthritis	0.000333	0.00351	CbGpPWpGaD
Regorafenib—Nausea—Triamcinolone—psoriatic arthritis	0.000332	0.00208	CcSEcCtD
Regorafenib—Nausea—Methylprednisolone—psoriatic arthritis	0.000331	0.00208	CcSEcCtD
Regorafenib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.00033	0.00348	CbGpPWpGaD
Regorafenib—RAF1—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000328	0.00346	CbGpPWpGaD
Regorafenib—FGFR1—DAP12 interactions—HLA-B—psoriatic arthritis	0.000324	0.00342	CbGpPWpGaD
Regorafenib—PDGFRA—DAP12 interactions—HLA-B—psoriatic arthritis	0.000323	0.00341	CbGpPWpGaD
Regorafenib—Vomiting—Dexamethasone—psoriatic arthritis	0.000323	0.00202	CcSEcCtD
Regorafenib—Vomiting—Betamethasone—psoriatic arthritis	0.000323	0.00202	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000321	0.00201	CcSEcCtD
Regorafenib—Rash—Dexamethasone—psoriatic arthritis	0.00032	0.00201	CcSEcCtD
Regorafenib—Rash—Betamethasone—psoriatic arthritis	0.00032	0.00201	CcSEcCtD
Regorafenib—Dermatitis—Betamethasone—psoriatic arthritis	0.00032	0.00201	CcSEcCtD
Regorafenib—Dermatitis—Dexamethasone—psoriatic arthritis	0.00032	0.00201	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000319	0.002	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—psoriatic arthritis	0.000318	0.002	CcSEcCtD
Regorafenib—Headache—Betamethasone—psoriatic arthritis	0.000318	0.00199	CcSEcCtD
Regorafenib—Headache—Dexamethasone—psoriatic arthritis	0.000318	0.00199	CcSEcCtD
Regorafenib—Asthenia—Prednisone—psoriatic arthritis	0.000317	0.00199	CcSEcCtD
Regorafenib—Pain—Methotrexate—psoriatic arthritis	0.000316	0.00198	CcSEcCtD
Regorafenib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000314	0.00331	CbGpPWpGaD
Regorafenib—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000314	0.00331	CbGpPWpGaD
Regorafenib—ABL1—skin of body—psoriatic arthritis	0.000314	0.0365	CbGeAlD
Regorafenib—KDR—tendon—psoriatic arthritis	0.000309	0.036	CbGeAlD
Regorafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000305	0.00322	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000304	0.00321	CbGpPWpGaD
Regorafenib—Diarrhoea—Prednisone—psoriatic arthritis	0.000302	0.0019	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000302	0.00189	CcSEcCtD
Regorafenib—Nausea—Dexamethasone—psoriatic arthritis	0.000301	0.00189	CcSEcCtD
Regorafenib—Nausea—Betamethasone—psoriatic arthritis	0.000301	0.00189	CcSEcCtD
Regorafenib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—psoriatic arthritis	0.000298	0.00314	CbGpPWpGaD
Regorafenib—RAF1—Ceramide signaling pathway—TNF—psoriatic arthritis	0.000295	0.00311	CbGpPWpGaD
Regorafenib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000292	0.00183	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000292	0.00183	CcSEcCtD
Regorafenib—PDGFRB—DAP12 interactions—HLA-B—psoriatic arthritis	0.000291	0.00307	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—MEFV—psoriatic arthritis	0.000283	0.00298	CbGpPWpGaD
Regorafenib—Vomiting—Prednisone—psoriatic arthritis	0.000281	0.00176	CcSEcCtD
Regorafenib—Rash—Prednisone—psoriatic arthritis	0.000279	0.00175	CcSEcCtD
Regorafenib—Dermatitis—Prednisone—psoriatic arthritis	0.000278	0.00175	CcSEcCtD
Regorafenib—Headache—Prednisone—psoriatic arthritis	0.000277	0.00174	CcSEcCtD
Regorafenib—PDGFRB—tendon—psoriatic arthritis	0.000268	0.0312	CbGeAlD
Regorafenib—Asthenia—Methotrexate—psoriatic arthritis	0.000265	0.00166	CcSEcCtD
Regorafenib—RAF1—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000265	0.00279	CbGpPWpGaD
Regorafenib—Nausea—Prednisone—psoriatic arthritis	0.000262	0.00165	CcSEcCtD
Regorafenib—FGFR2—Immune System—MEFV—psoriatic arthritis	0.00026	0.00274	CbGpPWpGaD
Regorafenib—RAF1—DAP12 interactions—HLA-B—psoriatic arthritis	0.00026	0.00274	CbGpPWpGaD
Regorafenib—TEK—Hemostasis—NOS2—psoriatic arthritis	0.000256	0.0027	CbGpPWpGaD
Regorafenib—KIT—Immune System—MEFV—psoriatic arthritis	0.000255	0.00269	CbGpPWpGaD
Regorafenib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000253	0.00159	CcSEcCtD
Regorafenib—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000253	0.00266	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—HLA-C—psoriatic arthritis	0.000249	0.00262	CbGpPWpGaD
Regorafenib—PDGFRA—Allograft Rejection—TNF—psoriatic arthritis	0.000247	0.0026	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—MEFV—psoriatic arthritis	0.000242	0.00255	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—MEFV—psoriatic arthritis	0.000242	0.00255	CbGpPWpGaD
Regorafenib—ABL1—tendon—psoriatic arthritis	0.000239	0.0278	CbGeAlD
Regorafenib—FGFR2—Adaptive Immune System—REL—psoriatic arthritis	0.000238	0.00251	CbGpPWpGaD
Regorafenib—MAPK11—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000235	0.00248	CbGpPWpGaD
Regorafenib—Vomiting—Methotrexate—psoriatic arthritis	0.000235	0.00147	CcSEcCtD
Regorafenib—KIT—Adaptive Immune System—REL—psoriatic arthritis	0.000234	0.00247	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.000233	0.00246	CbGpPWpGaD
Regorafenib—Rash—Methotrexate—psoriatic arthritis	0.000233	0.00146	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—psoriatic arthritis	0.000233	0.00146	CcSEcCtD
Regorafenib—Headache—Methotrexate—psoriatic arthritis	0.000231	0.00145	CcSEcCtD
Regorafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.000229	0.00241	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HLA-C—psoriatic arthritis	0.000228	0.00241	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—HLA-C—psoriatic arthritis	0.000224	0.00236	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000224	0.00236	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—REL—psoriatic arthritis	0.000222	0.00234	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—REL—psoriatic arthritis	0.000222	0.00234	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000219	0.00231	CbGpPWpGaD
Regorafenib—Nausea—Methotrexate—psoriatic arthritis	0.000219	0.00138	CcSEcCtD
Regorafenib—PDGFRB—Immune System—MEFV—psoriatic arthritis	0.000218	0.00229	CbGpPWpGaD
Regorafenib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000217	0.00229	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000215	0.00227	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HLA-C—psoriatic arthritis	0.000213	0.00224	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HLA-C—psoriatic arthritis	0.000212	0.00224	CbGpPWpGaD
Regorafenib—ABL1—Immune System—MEFV—psoriatic arthritis	0.000212	0.00224	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000204	0.00216	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000204	0.00215	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—REL—psoriatic arthritis	0.0002	0.0021	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000198	0.00208	CbGpPWpGaD
Regorafenib—NTRK1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000194	0.00205	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MEFV—psoriatic arthritis	0.000194	0.00205	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HLA-C—psoriatic arthritis	0.000191	0.00202	CbGpPWpGaD
Regorafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000189	0.00199	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HLA-C—psoriatic arthritis	0.000186	0.00197	CbGpPWpGaD
Regorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000184	0.00194	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000184	0.00194	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—NOD2—psoriatic arthritis	0.000183	0.00193	CbGpPWpGaD
Regorafenib—CYP2B6—skin of body—psoriatic arthritis	0.000182	0.0212	CbGeAlD
Regorafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.00018	0.0019	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—REL—psoriatic arthritis	0.000178	0.00188	CbGpPWpGaD
Regorafenib—NTRK1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000175	0.00185	CbGpPWpGaD
Regorafenib—RAF1—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000175	0.00185	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HLA-C—psoriatic arthritis	0.000171	0.0018	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—NOD2—psoriatic arthritis	0.000168	0.00177	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—NOD2—psoriatic arthritis	0.000165	0.00174	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000164	0.00173	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—REL—psoriatic arthritis	0.000157	0.00166	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—NOD2—psoriatic arthritis	0.000157	0.00165	CbGpPWpGaD
Regorafenib—BRAF—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000156	0.00165	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—NOD2—psoriatic arthritis	0.000156	0.00165	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000152	0.0016	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—HLA-B—psoriatic arthritis	0.000147	0.00155	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-C—psoriatic arthritis	0.000145	0.00153	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—REL—psoriatic arthritis	0.000145	0.00152	CbGpPWpGaD
Regorafenib—KIT—Immune System—REL—psoriatic arthritis	0.000142	0.0015	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—NOD2—psoriatic arthritis	0.000141	0.00148	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—NOD2—psoriatic arthritis	0.000137	0.00145	CbGpPWpGaD
Regorafenib—FGFR1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000135	0.00143	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HLA-B—psoriatic arthritis	0.000135	0.00142	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—REL—psoriatic arthritis	0.000135	0.00142	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—REL—psoriatic arthritis	0.000134	0.00142	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-C—psoriatic arthritis	0.000133	0.0014	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—HLA-B—psoriatic arthritis	0.000133	0.0014	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-C—psoriatic arthritis	0.000131	0.00138	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—CRP—psoriatic arthritis	0.00013	0.00137	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.00013	0.00137	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000127	0.00134	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HLA-B—psoriatic arthritis	0.000126	0.00133	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HLA-B—psoriatic arthritis	0.000126	0.00132	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—NOD2—psoriatic arthritis	0.000125	0.00132	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-C—psoriatic arthritis	0.000124	0.00131	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-C—psoriatic arthritis	0.000124	0.0013	CbGpPWpGaD
Regorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000122	0.00129	CbGpPWpGaD
Regorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000122	0.00128	CbGpPWpGaD
Regorafenib—PDGFRB—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000121	0.00128	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—REL—psoriatic arthritis	0.000121	0.00128	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000121	0.00127	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000121	0.00127	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—CRP—psoriatic arthritis	0.000119	0.00126	CbGpPWpGaD
Regorafenib—ABL1—Immune System—REL—psoriatic arthritis	0.000118	0.00124	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—CRP—psoriatic arthritis	0.000117	0.00124	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HLA-B—psoriatic arthritis	0.000113	0.00119	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-C—psoriatic arthritis	0.000111	0.00117	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—CRP—psoriatic arthritis	0.000111	0.00117	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—CRP—psoriatic arthritis	0.000111	0.00117	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HLA-B—psoriatic arthritis	0.00011	0.00116	CbGpPWpGaD
Regorafenib—EPHA2—Developmental Biology—TNF—psoriatic arthritis	0.00011	0.00116	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.00011	0.00116	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000109	0.00115	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-C—psoriatic arthritis	0.000109	0.00114	CbGpPWpGaD
Regorafenib—RAF1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000108	0.00114	CbGpPWpGaD
Regorafenib—RAF1—Immune System—REL—psoriatic arthritis	0.000108	0.00114	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000108	0.00114	CbGpPWpGaD
Regorafenib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000107	0.00113	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—NOD2—psoriatic arthritis	0.000107	0.00112	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000102	0.00108	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000102	0.00108	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HLA-B—psoriatic arthritis	0.000101	0.00106	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—CRP—psoriatic arthritis	0.0001	0.00105	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-C—psoriatic arthritis	9.93e-05	0.00105	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—NOS2—psoriatic arthritis	9.87e-05	0.00104	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—NOD2—psoriatic arthritis	9.78e-05	0.00103	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	9.77e-05	0.00103	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—CRP—psoriatic arthritis	9.75e-05	0.00103	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-B—psoriatic arthritis	9.68e-05	0.00102	CbGpPWpGaD
Regorafenib—KIT—Immune System—NOD2—psoriatic arthritis	9.61e-05	0.00101	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	9.34e-05	0.000984	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	9.2e-05	0.000969	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—NOD2—psoriatic arthritis	9.12e-05	0.000961	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—NOD2—psoriatic arthritis	9.1e-05	0.000959	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—NOS2—psoriatic arthritis	9.03e-05	0.000952	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—CRP—psoriatic arthritis	8.91e-05	0.00094	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-B—psoriatic arthritis	8.57e-05	0.000903	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	8.2e-05	0.000864	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—NOD2—psoriatic arthritis	8.19e-05	0.000864	CbGpPWpGaD
Regorafenib—ABL1—Immune System—NOD2—psoriatic arthritis	7.99e-05	0.000842	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-B—psoriatic arthritis	7.87e-05	0.000829	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—TNF—psoriatic arthritis	7.75e-05	0.000817	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-B—psoriatic arthritis	7.73e-05	0.000814	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CRP—psoriatic arthritis	7.57e-05	0.000798	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-B—psoriatic arthritis	7.33e-05	0.000773	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-B—psoriatic arthritis	7.31e-05	0.000771	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NOD2—psoriatic arthritis	7.3e-05	0.00077	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-DRB1—psoriatic arthritis	7.25e-05	0.000765	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CRP—psoriatic arthritis	6.95e-05	0.000733	CbGpPWpGaD
Regorafenib—KIT—Immune System—CRP—psoriatic arthritis	6.83e-05	0.00072	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—TNF—psoriatic arthritis	6.67e-05	0.000703	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-DRB1—psoriatic arthritis	6.66e-05	0.000702	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-B—psoriatic arthritis	6.59e-05	0.000695	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-DRB1—psoriatic arthritis	6.54e-05	0.000689	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CRP—psoriatic arthritis	6.48e-05	0.000683	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CRP—psoriatic arthritis	6.47e-05	0.000682	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-B—psoriatic arthritis	6.42e-05	0.000677	CbGpPWpGaD
Regorafenib—BRAF—Disease—NOS2—psoriatic arthritis	6.32e-05	0.000666	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-DRB1—psoriatic arthritis	6.21e-05	0.000654	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-DRB1—psoriatic arthritis	6.19e-05	0.000653	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-B—psoriatic arthritis	5.87e-05	0.000619	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NOS2—psoriatic arthritis	5.86e-05	0.000617	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CRP—psoriatic arthritis	5.82e-05	0.000614	CbGpPWpGaD
Regorafenib—KIT—Disease—NOS2—psoriatic arthritis	5.75e-05	0.000606	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—TNF—psoriatic arthritis	5.7e-05	0.000601	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CRP—psoriatic arthritis	5.68e-05	0.000598	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-DRB1—psoriatic arthritis	5.58e-05	0.000588	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NOS2—psoriatic arthritis	5.46e-05	0.000575	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NOS2—psoriatic arthritis	5.44e-05	0.000574	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-DRB1—psoriatic arthritis	5.44e-05	0.000573	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CRP—psoriatic arthritis	5.19e-05	0.000547	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—TNF—psoriatic arthritis	5e-05	0.000527	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-DRB1—psoriatic arthritis	4.97e-05	0.000524	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NOS2—psoriatic arthritis	4.9e-05	0.000517	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	4.61e-05	0.000486	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—psoriatic arthritis	4.57e-05	0.000482	CbGpPWpGaD
Regorafenib—RAF1—Disease—NOS2—psoriatic arthritis	4.37e-05	0.000461	CbGpPWpGaD
